XUNFEIHEALTH will convene its 2026 Annual General Meeting at 9:30 a.m. on Friday, 26 June 2026, in the company’s meeting room at 666 West Wangjiang Road, Shushan District, Hefei, Anhui Province.

Key ordinary resolutions: • Board Work and Annual Reports: Shareholders will review the board’s 2025 work report and the full 2025 annual report. • Bank Credit Facilities: Management seeks approval to apply for new comprehensive credit lines. • 2025 Financial Settlement and Profit Distribution: The meeting will vote on the final accounts and the profit distribution plan for 2025. • 2026 Remuneration: Directors’ and senior management’s 2026 compensation package requires shareholder endorsement. • Auditor Appointment: The board proposes Deloitte Touche Tohmatsu as external auditor for 2026, with authority to set its fees. • Loss Coverage: Shareholders will consider a resolution acknowledging uncovered losses that exceed one-third of paid-up share capital.

Key special resolutions: • Subsidiary Guarantees: Management requests authority to provide guarantees for subsidiaries. • Business Scope & Articles Amendment: Proposed changes to the company’s business scope will trigger corresponding amendments to the Articles of Association. • General Share Issuance Mandate: The board seeks authority to issue up to 20% of the total issued shares (excluding treasury shares) during the “Relevant Period,” including any related amendments to the Articles and procedural actions. • H-Share Repurchase Mandate: Management asks for a mandate to repurchase up to 10% of issued H-shares (excluding treasury shares) in the same timeframe, with power to adjust registered capital and amend the Articles accordingly.

Procedural notes: • All resolutions will be decided by poll. • The H-share register will be closed from 23 June to 26 June 2026, inclusive; transfers must be lodged by 4:30 p.m. on 22 June 2026 to qualify for voting. • Proxy forms must be submitted no later than 9:30 a.m. on 25 June 2026.

Board composition at the notice date comprises one executive director, three non-executive directors and three independent non-executive directors.

The AGM agenda reflects management’s focus on formalising 2025 financial results, addressing capital structure flexibility via issuance and buyback mandates, and resolving uncovered losses to protect shareholder interests.